Boston Scientific’s $1.07bn asset transaction deal with Lumenis was the medical devices industry’s biggest cross border deal of Q1 2021 as cross border deals worth $6.67bn were announced globally in the quarter, according to GlobalData’s deals database.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 5.5% over the previous quarter and a drop of 16.4% when compared with the last four-quarter average of $7.98bn.

In terms of number of cross border deals, the sector saw a rise of 17.14% with 135 deals in Q1 2021 against the average of 115.25 deals in the last four-quarters.

In value terms, North America led the activity with cross border deals worth $2.73bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

medical devices industry cross border deals in Q1 2021: Top deals

The top five medical devices industry cross border deals accounted for 53.8% of the overall value during Q1 2021.

The combined value of the top five cross border deals stood at $3.59bn, against the overall value of $6.67bn recorded for the quarter.

The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:

1) Boston Scientific’s $1.07bn asset transaction deal with Lumenis

2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific

3) Koninklijke Philips’ $635m acquisition of Capsule Technologies

4) The $591m acquisition of Oxford Immunotec by PerkinElmer

5) Savaria’s acquisition of Handicare Group for $409.7m.